GENEVA, Jan. 21 /CNW/ - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY(1) Phase III trial using Cladribine Tablets (Merck Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine(2). The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
"The CLARITY trial represents an important step forward in multiple sclerosis research, and we are pleased that the results have been published in The New England Journal of Medicine," says Dr. Gavin Giovannoni, principal investigator of the CLARITY study and lead author on the publication, from Queen Mary University London, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom.
The authors report in the publication that the primary endpoint and key secondary endpoints of the CLARITY trial were met. The CLARITY data were presented at the 61st Annual Meeting of the American Academy of Neurology (AAN) in April 2009 and at other international scientific meetings.
1 CLARITY: CLAdRIbine Tablets Treating MS OrallY
2 Giovannoni G et al. A placebo-Controlled Trial of Oral Cladribine for
Relapsing Multiple Sclerosis; available on www.nejm.org; will also be
published in the February 4, 2010 printed issue of The New England
Journal of Medicine
CLARITY study design
The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled, international trial. It randomized 1,326 patients with relapsing-remitting MS according to the revised McDonald criteria. Study participants were randomized to one of three different treatment groups consisting of two different dose regimens of Cladribine Tablets or matching placebo tablets (1:1:1 ratio). Cladribine Tablets were given in two (3.5 mg/kg total dose) or four (5.25 mg/kg total dose) treatment courses in the first year, with each course consisting of once daily administration for four to five consecutive days (depending on patient weight), which means study patients took Cladribine Tablets for 8 to 20 days during the year. In the second year, two treatment courses were administered to all patient groups, meaning that patients took Cladribine Tablets for 8 to 10 days during the year.
The primary endpoint of the CLARITY study was the relapse rate over 96 weeks. Secondary endpoints included MRI endpoints, proportion of subjects relapse-free and disability progression at 96 weeks.
About Cladribine Tablets
Merck Serono's oral formulation of cladribine (Cladribine Tablets) is an investigational treatment for patients with relapsing forms of multiple sclerosis (MS). Cladribine is a small molecule that may interfere with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS.
The clinical development program for Cladribine Tablets includes:
- The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study and its
extension: a two-year Phase III placebo-controlled trial designed to
evaluate the efficacy and safety of Cladribine Tablets as a
monotherapy in patients with relapsing-remitting MS and its two-year
extension designed to provide data on the long-term safety and
efficacy of extended administration of Cladribine Tablets for up to
- The ORACLE MS (ORAl CLadribine in Early MS) study: a two-year Phase
III placebo-controlled trial designed to evaluate the efficacy and
safety of Cladribine Tablets as a monotherapy in patients at risk of
developing MS (patients who have experienced a first clinical event
suggestive of MS). This trial was announced in September 2008.
- The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients
With Active Relapsing Disease) study: a Phase II placebo-controlled
trial designed primarily to evaluate the safety and tolerability of
adding Cladribine Tablets treatment to patients with relapsing forms
of MS, who have experienced breakthrough disease while on established
interferon-beta therapy. This trial was announced in January 2007.
About multiple sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that more than two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
About Merck Serono
Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD Serono operates through separately incorporated affiliates.
Merck Serono has leading brands serving patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiometabolic diseases. Not all products are available in all markets.
With an annual R&D expenditure of around (euro) 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.
Merck is a global pharmaceutical and chemical company with total revenues of (euro) 7.6 billion in 2008, a history that began in 1668, and a future shaped by approximately 33,000 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
For more information, please visit www.merckserono.com or www.merck.de
About EMD Serono
EMD Serono Canada provides innovative drug therapies that address unmet medical needs in the areas of neurodegenerative diseases, fertility and endocrinology. EMD Serono is a division of EMD Canada Inc. EMD Canada Inc. is an affiliate of Merck Serono*, Geneva, Switzerland. Merck Serono* is a division of Merck KGaA, Darmstadt, Germany. For more information, please go to www.emdserono.ca.
SOURCE Merck Serono
For further information: For further information: To book an interview, please contact: Noemie Wiggett, Environics Communications, (416) 969-2661, firstname.lastname@example.org